Domov › Skvamóznocelulárny karcinóm hlavy a krku › Utah
Klinické štúdie Skvamóznocelulárny karcinóm hlavy a krku v štáte Utah
21 štúdií pre Skvamóznocelulárny karcinóm hlavy a krku hľadá účastníkov v zariadeniach v štáte Utah.
Mestá v štáte Utah
Oficiálny text štúdie (anglicky)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Farmington Health Center, Farmington
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06992427A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06465069A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 4, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07085091BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Huntsman Cancer Institute, Salt Lake City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Utah Huntsman Cancer Institute, Salt Lake City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06385080Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT05267626A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- START Center for Cancer Research, West Valley City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07109726ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT05059444Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 8. 2026 · NCT05985655A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT06242470A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT06330064A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 7. 2026 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 7. 2026 · NCT05768139Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 6. 2026 · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START Mountain Region, LLC, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 6. 2026 · NCT07503808Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 6. 2026 · NCT07517198Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 2. 2026 · NCT07044635Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 2. 2026 · NCT07030257VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Utah Cancer Specialists (site 203), Salt Lake City
Prebieha náborFáza 1/2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 11. 12. 2025 · NCT03556228Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.